The estimated Net Worth of William G. Rice is at least $2.67 Milion dollars as of 19 September 2022. William Rice owns over 10,000 units of Aptose Biosciences Inc stock worth over $134,040 and over the last 6 years he sold APTO stock worth over $1,021,791. In addition, he makes $1,511,900 as Chairman of the Board, President a Chief Executive Officer at Aptose Biosciences Inc.
Sign up
William Rice APTO stock SEC Form 4 insiders trading
William has made over 11 trades of the Aptose Biosciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of APTO stock worth $6,800 on 19 September 2022.
The largest trade he's ever made was selling 168,891 units of Aptose Biosciences Inc stock on 10 July 2020 worth over $1,021,791. On average, William trades about 14,106 units every 68 days since 2019. As of 19 September 2022 he still owns at least 363,252 units of Aptose Biosciences Inc stock.
You can see the complete history of William Rice stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Rice biography
Dr. William Glenn Rice Ph.D. serves as Chairman of the Board, President, Chief Executive Officer of the Company. Prior to joining Aptose, Dr. Rice served as the President, Chief Executive Officer and Chairman of the board of Cylene Pharmaceuticals, Inc., a private biotechnology company from 2003 to 2013. Prior to Cylene, Dr. Rice was the founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. from 1990 to 2003. He also served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer InstituteFrederick Cancer Research and Development Center from 1992 to 1998, and served as a faculty member in the division of Pediatric Hematology and Oncology at Emory University School of Medicine from 1989 to 1992. Dr. Rice received his Ph.D. from Emory University Department of Biochemistry. Dr. Rice continues to serve as the Chairman of the board of Cylene and is a member of the board of directors of Oncolytics Biotech Inc. (2015 to present)*. Dr. Rice makes valuable contributions to the Board based on his Ph.D. in Biochemistry, and his over 25 years of experience in the biotechnology industry as a senior executive and as a corporate director.
What is the salary of William Rice?
As the Chairman of the Board, President a Chief Executive Officer of Aptose Biosciences Inc, the total compensation of William Rice at Aptose Biosciences Inc is $1,511,900. There are no executives at Aptose Biosciences Inc getting paid more.
How old is William Rice?
William Rice is 61, he's been the Chairman of the Board, President a Chief Executive Officer of Aptose Biosciences Inc since 2013. There are 6 older and 6 younger executives at Aptose Biosciences Inc. The oldest executive at Aptose Biosciences Inc is Denis Burger, 75, who is the Lead Independent Director.
What's William Rice's mailing address?
William's mailing address filed with the SEC is C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO, A6, M2J 4R3.
Insiders trading at Aptose Biosciences Inc
Over the last 6 years, insiders at Aptose Biosciences Inc have traded over $2,827,381 worth of Aptose Biosciences Inc stock and bought 538,629 units worth $767,189 . The most active insiders traders include Erich Platzer, Bernd R. Seizinger a William G. Rice. On average, Aptose Biosciences Inc executives and independent directors trade stock every 59 days with the average trade being worth of $14,277. The most recent stock trade was executed by Bernd R. Seizinger on 22 September 2023, trading 17,000 units of APTO stock currently worth $53,380.
What does Aptose Biosciences Inc do?
aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt
What does Aptose Biosciences Inc's logo look like?
Complete history of William Rice stock trades at Aptose Biosciences Inc
Aptose Biosciences Inc executives and stock owners
Aptose Biosciences Inc executives and other stock owners filed with the SEC include:
-
William Rice,
Chairman of the Board, President, Chief Executive Officer -
Gregory Chow,
Chief Financial Officer, Executive Vice President -
Jotin Marango,
Senior Vice President, Chief Business Officer -
Dr. William G. Rice Ph.D.,
Chairman, Pres & CEO -
Dr. Jotin Marango Ph.D., M.D.,
Sr. VP, CFO, Chief Accounting Officer & Chief Bus. Officer -
Dr. Rafael Bejar M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Denis Burger,
Lead Independent Director -
Caroline Loewy,
Independent Director -
Carol Ashe,
Independent Director -
Warren Whitehead,
Independent Director -
Mark Vincent,
Independent Director -
Erich Platzer,
Independent Director -
Rafael Bejar,
Senior Vice President, Chief Medical Officer -
Roger Davies B.Sc.,
VP of Operations -
Bernd R. Seizinger,
-
Fletcher Payne,
Sr VP and CFO -
Philippe Ledru,